Investors Are Bullish on Edwards Lifesciences - Here's What You Need to Know.

Edwards Lifesciences shares rose 3.4% this evening to a price of $77.76. The stock is still trading within range of its average target price of $77.65, and over the last 52 weeks, it has recorded a 2.3% performance. Analysts have given the large-cap Specialty Industrial Machinery stock target prices ranging from $57.0 to $96.0 dollars per share, with an average rating of buy.

The stock has a very low short interest at 1.7%, and a short ratio of 2.26. The company's insiders own 0.84% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 85.0% of Edwards Lifesciences's shares being owned by this investor type.

Institutions Invested in Edwards Lifesciences

Date Reported Holder Percentage Shares Value
2023-09-30 Vanguard Group Inc 9% 51,633,416 $4,015,014,538
2023-09-30 Blackrock Inc. 8% 51,375,446 $3,994,954,790
2023-09-30 Capital International Investors 5% 30,253,728 $2,352,529,953
2023-09-30 State Street Corporation 4% 26,447,736 $2,056,576,007
2023-09-30 Alliancebernstein L.P. 4% 22,741,712 $1,768,395,573
2023-09-30 Bank Of New York Mellon Corporation 3% 17,608,841 $1,369,263,513
2023-09-30 Wellington Management Group, LLP 3% 16,434,401 $1,277,939,056
2023-09-30 Brown Advisory Inc. 2% 15,133,146 $1,176,753,465
2023-09-30 Geode Capital Management, LLC 2% 12,691,799 $986,914,317
2022-12-31 Norges Bank Investment Management 1% 8,824,423 $686,187,151

Besides an analyst consensus of little upside potential, other market factors point to there being mixed market sentiment on Edwards Lifesciences.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.